Scholar Rock (NASDAQ:SRRK) Issues Earnings Results, Beats Expectations By $0.04 EPS

Scholar Rock (NASDAQ:SRRK) posted its earnings results on Tuesday. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04, FiscalAI reports. The company had revenue of $0.57 million for the quarter, compared to analysts’ expectations of $0.30 million. During the same quarter in the prior year, the company earned ($0.90) EPS.

Here are the key takeaways from Scholar Rock’s conference call:

• ISEMBYLD’s U.S. launch showed broad early demand: enrollments came from across the country, included treatment-naive patients as well as children and adults, and reached more than one-third of the top 140 SMA treatment centers within six weeks.
• Access delays are likely to push many initial infusions into 2027. The company said prescription-to-infusion timelines can exceed 60–90 days as patients navigate prior authorization, payer policies, and hospital formularies; an ISEMBYLD-specific J-code is expected April 1, 2027.
• Global regulatory progress advanced: apitegromab’s European application was resubmitted and validated, with a CHMP opinion expected in the first half of 2027, while Japan accepted its application for priority review, supporting a potential launch near year-end 2027.
• The company strengthened its financial position with a $205 million agreement to sell its priority review voucher. Scholar Rock reported $413.6 million in cash, equivalents, and marketable securities at quarter-end and said it does not need an equity offering at this time.
• Pipeline programs continued to progress: dosing began in the phase II FORGE study of apitegromab in FSHD, enrollment is ongoing in the under-two OPAL study, and SRK-439 phase I dosing is progressing, with top-line data expected by year-end and an update planned for early 2027.

Scholar Rock Trading Down 6.9%

Shares of NASDAQ:SRRK opened at $48.00 on Wednesday. Scholar Rock has a 52-week low of $28.97 and a 52-week high of $61.76. The stock has a market cap of $5.85 billion, a price-to-earnings ratio of -13.91 and a beta of 0.78. The company has a quick ratio of 7.02, a current ratio of 7.02 and a debt-to-equity ratio of 0.77. The business has a 50-day moving average price of $46.83 and a 200-day moving average price of $48.22.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on SRRK. Piper Sandler boosted their target price on shares of Scholar Rock from $60.00 to $75.00 and gave the stock an “overweight” rating in a report on Tuesday, September 15th. Citigroup boosted their target price on shares of Scholar Rock from $60.00 to $74.00 and gave the stock a “buy” rating in a research report on Monday, September 14th. HC Wainwright upped their price target on shares of Scholar Rock from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Tuesday, September 15th. BMO Capital Markets raised their price target on shares of Scholar Rock from $76.00 to $84.00 and gave the stock an “outperform” rating in a report on Monday, September 14th. Finally, JPMorgan Chase & Co. raised their price target on shares of Scholar Rock from $63.00 to $70.00 and gave the stock an “overweight” rating in a report on Monday, September 21st. Four research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $67.67.

Scholar Rock News Roundup

Here are the key news stories impacting Scholar Rock this week:

• Positive Sentiment: Scholar Rock reported a Q3 loss of $0.81 per share, narrower than analysts’ estimates of $0.85–$0.87, and revenue of $0.57 million, above the $0.30 million consensus. The loss also narrowed from $0.90 per share a year earlier. Zacks earnings report
• Positive Sentiment: The quarter marked Scholar Rock’s first product revenue, following the launch of ISEMBYLD—a commercial milestone that could support future growth if sales build. First product revenue article
• Positive Sentiment: HC Wainwright maintained a Buy rating and a $70 price target while issuing 2027 quarterly loss estimates, offering a favorable analyst view. Scholar Rock analyst coverage
• Negative Sentiment: Despite the beat, reported revenue was only $0.57 million and the company remained loss-making. Investors may be weighing the gap between initial product sales and the scale needed to materially improve results.

Insider Buying and Selling

In other news, Director Srinivas Akkaraju bought 146,970 shares of the company’s stock in a transaction that occurred on Monday, October 26th. The shares were purchased at an average price of $41.59 per share, for a total transaction of $6,112,482.30. Following the completion of the transaction, the director directly owned 6,380,517 shares in the company, valued at approximately $265,365,702.03. This represents a 2.36% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 10.30% of the stock is currently owned by corporate insiders.

About Scholar Rock

Scholar Rock is a biopharmaceutical company based in Cambridge, Massachusetts, that develops medicines targeting growth factors and signaling proteins involved in disease. Its research has focused on the transforming growth factor beta (TGF-β) superfamily, which plays roles in processes including muscle development and immune regulation. The company’s lead program has been apitegromab, a selective inhibitor of myostatin developed for spinal muscular atrophy (SMA). Scholar Rock has studied the medicine as a potential treatment alongside existing SMA therapies, with the goal of improving patients’ motor function.